BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study-Reference-Cited by-同舟云学术

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

Published:2024-07 Issue:7 Volume:25 Page:901-911
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ma Yuxiang,Huang Yan,Zhao Yuanyuan,Zhao Shen,Xue Jinhui,Yang Yunpeng,Fang Wenfeng,Guo Ye,Han Yaqian,Yang Kunyu,Li Yongsheng,Yang Jun,Fu Zhenming,Chen Gang,Chen Likun,Zhou Ningning,Zhou Ting,Zhang Yaxiong,Zhou Huaqiang,Liu Qianwen,Zhu Yi,Zhu Hai,Xiao Sa,Zhang Li,Zhao Hongyun

Publisher

Elsevier BV

Reference30 articles.

1. Antitumour immunity regulated by aberrant ERBB family signalling;Kumagai;Nat Rev Cancer,2021

2. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014

3. Peptides for dual targeting of ErbB1 and ErbB2: blocking EGFR cell signaling transduction pathways for cancer chemotherapy;Patnaik;Curr Mol Pharmacol,2023

4. Targeting HER3 for cancer treatment: a new horizon for an old target;Uliano;ESMO Open,2023

5. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies;Tarantino;CA Cancer J Clin,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

2. The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases;Pharmaceutics;2024-07-02